SWEDISH ORPHAN BIOVITRUM AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 261 SEK | +0.62% |
|
+1.95% | -2.25% |
| Mar. 14 | Certain Shares of Swedish Orphan Biovitrum AB are subject to a Lock-Up Agreement Ending on 14-MAR-2024. | CI |
| Feb. 13 | Sobi to Expand in South Korea via Rare Disease JV with Handok | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
261
SEK
Average target price
314.1
SEK
Spread / Average Target
+20.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.25% | 8.07B | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| -24.88% | 27.69B | |
| +53.61% | 24.28B | |
| -8.08% | 17.09B | |
| -33.74% | 13.67B | |
| -16.63% | 11.86B | |
| -11.19% | 11.79B | |
| +1.05% | 7.51B |
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Sanofi, Sobi's Rare Bleeding Disorder Drug Shown Safe for Kids in Late-stage Study
